For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

EXPLORE THE BIOLOGY

Peptides for Weight Loss & Metabolism: What the Human Evidence Shows

Content updated · how dates work

Appetite, blood sugar, and energy metabolism.

This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.

Weight & metabolism: what the human evidence shows

Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for weight & metabolism: the best trial may be small, negative or about a different condition. No doses.

PeptideStrongest human evidence in our sourcesFDAHuman safety data
FDA-approved medicine (11)Approved for the specific uses on its label, which may not be this goal.
DulaglutideREWIND (2019) · Human randomized trial
The combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 12.0% with dulaglutide and 13.4% with placebo. Hazard ratio: 0.88 (95% confidence interval 0.79–0.99).
Limitation: This was a cardiovascular-risk population with diabetes. The results do not establish a longevity benefit in healthy people. Gastrointestinal events were more frequent with dulaglutide.
Studied: 9,901 adults aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors.
FDA-approvedFDA label
ExenatideEXSCEL (2017) · Human randomized trial
The main cardiovascular composite occurred in 11.4% versus 12.2%; hazard ratio 0.91 (95% CI 0.83–1.00). Noninferiority was met, but superiority was not (P=0.06).
Limitation: Meeting a cardiovascular safety criterion is different from proving cardiovascular benefit. Results concern the once-weekly preparation and should not be relabeled as an obesity trial.
Studied: 14,752 adults with type 2 diabetes.
FDA-approvedFDA label
GlucagonNasal versus intramuscular glucagon (2016) · Human randomized crossover trial
Success occurred in 98.7% of nasal visits versus 100% of intramuscular visits. Mean recovery times were 16 and 13 minutes, respectively.
Limitation: This was a controlled rescue-treatment study, not a comparison of unsupervised use in every emergency. The nasal and injected products have different delivery systems.
Studied: 75 adults with type 1 diabetes under supervised experimental hypoglycemia.
FDA-approvedFDA label
Human insulinDCCT (1993) · Human randomized trial
Intensive management reduced development of retinopathy by 76% in the primary-prevention group and slowed progression by 54% in the other group. Severe hypoglycemia was more frequent.
Limitation: This tested a treatment strategy including monitoring, not one modern brand versus another. It demonstrates the tradeoff between complication reduction and hypoglycemia risk.
Studied: 1,441 people with type 1 diabetes, with or without early retinopathy.
FDA-approvedFDA label
LiraglutideLEADER (2016) · Human randomized trial
The cardiovascular composite occurred in 13.0% versus 14.9%; hazard ratio 0.87 (95% CI 0.78–0.97). Gastrointestinal events were the commonest reason for stopping treatment.
Limitation: The 1.9-percentage-point difference describes this population and follow-up. This was not a trial of otherwise healthy people or the separate weight-management product indication.
Studied: 9,340 adults with type 2 diabetes and high cardiovascular risk.
FDA-approvedFDA label
LixisenatideELIXA (2015) · Human randomized trial
The primary cardiovascular composite occurred in 13.4% with lixisenatide and 13.2% with placebo: hazard ratio 1.02 (95% CI 0.89–1.17). Noninferiority was established; superiority was not.
Limitation: The finding supports cardiovascular safety within the trial’s prespecified framework. It does not establish cardiovascular benefit. Heart-failure hospitalization and mortality were not significantly different. Sanofi funded the trial.
Studied: 6,068 people with type 2 diabetes and an acute coronary event in the preceding 180 days.
FDA-approvedFDA label
OrforglipronATTAIN-1: orforglipron versus placebo for 72 weeks in adults with obesity (2025) · Human randomized phase 3 trial
Counting everyone randomized, average weight change at 72 weeks was -7.5%, -8.4% and -11.2% across the three dose levels versus -2.1% with placebo. On the highest dose, 54.6% lost at least 10% of their weight and 18.4% lost at least 20%. Waist size, blood pressure, triglycerides and non-HDL cholesterol also improved.
Limitation: The trial was funded by Eli Lilly, lasted 72 weeks and measured weight and risk factors, not heart attacks, strokes or deaths. No trial has compared orforglipron directly with injectable semaglutide or tirzepatide for weight loss, and results from separate trials are not a direct contest.
Studied: 3,127 adults with obesity, or overweight with a weight-related condition, without diabetes.
FDA-approvedFDA label
SemaglutideSTEP 1 (2021) · Human randomized trial
Mean weight change was −14.9% versus −2.4%, a 12.4-percentage-point estimated difference. Gastrointestinal effects were common.
Limitation: These are average results for a specific injectable regimen and trial population. The study is not a comparison with tirzepatide and cannot validate compounded or research-use products.
Studied: 1,961 adults with obesity, or overweight with a weight-related condition, without diabetes.
FDA-approvedFDA label
SetmelanotideSetmelanotide in POMC or LEPR deficiency (2020) · Human open-label phase 3 studies with withdrawal periods
At least 10% weight loss was reported in 8 of 10 POMC participants and 5 of 11 LEPR participants.
Limitation: This was not a full-year parallel placebo-controlled comparison. Small, genetically selected cohorts do not establish effectiveness in common obesity.
Studied: 10 participants with POMC deficiency and 11 with LEPR deficiency, aged six years or older.
FDA-approvedFDA label
TesamorelinHIV-associated abdominal-fat trial (2007) · Human randomized trial
Visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo. Some lipid measures also improved. IGF-I increased by 81.0% versus a 5.0% decrease with placebo. More tesamorelin recipients withdrew because of adverse events, despite no significant overall adverse-event difference.
Limitation: Visceral-fat change is not the same as total body-weight loss. The trial population and HIV-associated condition are central; long-term cardiovascular benefit was not established by this endpoint.
Studied: 412 people with HIV and abdominal fat accumulation; 86% were men.
FDA-approvedFDA label
TirzepatideSURMOUNT-1 (2022) · Human randomized trial
Mean weight reductions were 15.0%, 19.5%, and 20.9% across active groups versus 3.1% with placebo. Gastrointestinal effects were common.
Limitation: This trial cannot be compared directly with STEP 1 as if participants were randomized between the two drugs. Outcomes depend on population, duration, regimen, and handling of discontinuation.
Studied: 2,539 adults with obesity, or overweight and a weight-related complication, without diabetes.
FDA-approvedFDA label
Randomized human trials (13)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition.
CagrilintideCagrilintide dose-finding study (2021) · Human phase 2 randomized trial
Estimated mean weight reduction ranged from 6.0% to 10.8% across cagrilintide groups versus 3.0% with placebo in the trial-product analysis. Gastrointestinal and injection-site events were frequent.
Limitation: This is monotherapy evidence. It cannot be presented as the result for CagriSema or for an unidentified seller blend; longer-term outcomes require separate studies.
Studied: 706 adults with obesity, or overweight with hypertension or dyslipidemia, without diabetes.
Not approvedTrials only
EfpeglenatideAMPLITUDE-O (2021) · Human randomized trial
Major cardiovascular events occurred in 7.0% versus 9.2%: hazard ratio 0.73 (95% CI 0.58–0.92). The renal composite occurred in 13.0% versus 18.4%: hazard ratio 0.68.
Limitation: These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study.
Studied: 4,076 adults with type 2 diabetes and cardiovascular disease, or kidney disease plus an additional cardiovascular risk factor.
Not approvedTrials only
Eloralintide48-week phase 2 trial in adults with obesity or overweight (2025) · Human randomized phase 2 trial
Average weight change at 48 weeks ranged from about -9% in the lowest dose group to about -20% in the highest groups, versus -0.4% with placebo, and weight loss rose with dose. The most common side effects were nausea (11% to 64% across dose groups, versus 14% with placebo) and fatigue (0% to 46%, versus 12%); both were more common in the higher dose groups than in the lowest ones, though not in a steady pattern.
Limitation: One 48-week phase 2 trial of 263 people, run and funded by the manufacturer. It does not show effects on heart disease, long-term safety or whether the weight stays off, and it did not compare eloralintide with GLP-1 drugs or with cagrilintide. Phase 3 results are not expected until about 2028.
Studied: 263 adults aged 18 to 75 at 46 US research centers with a BMI of 30 or more, or 27 or more with at least one weight-related condition, and…
Not approvedTrials only
GhrelinGhrelin infusion and food intake (2001) · Human randomized crossover study
Energy intake was approximately 28% higher after ghrelin, and appetite ratings increased. The tested gastric-emptying measure did not change.
Limitation: An acute study in nine healthy people does not establish a chronic disease benefit, sustained weight change, or effects in cachexia.
Studied: Nine healthy volunteers.
Not approvedTrials only
L-CarnosineCarnosine in overweight and obese adults (2016) · Human randomized pilot trial
The supplemented group showed attenuation of increases in fasting insulin and insulin resistance. A subgroup analysis reported glucose-tolerance changes.
Limitation: Small pilot and subgroup findings do not establish prevention of type 2 diabetes or treatment of neurological disease.
Studied: 30 overweight or obese adults without diabetes.
Not approvedTrials only
MazdutideGLORY-1 (2025) · Human randomized trial
At week 32, mean weight change was −10.09% and −12.55% in the mazdutide groups versus +0.45% with placebo. At week 48, the corresponding changes were −11.00%, −14.01%, and +0.30%.
Limitation: The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent.
Studied: 610 Chinese adults aged 18–75 with obesity, or overweight and an associated condition.
Not approvedTrials only
MK-677Ibutamoren in healthy older adults (2008) · Human randomized trial
Fat-free mass increased with ibutamoren versus placebo, but strength and function did not improve. Fasting glucose increased and insulin sensitivity decreased.
Limitation: More fat-free mass does not establish stronger muscles, improved independence, or a longevity benefit.
Studied: 65 healthy adults aged 60–81.
Not approvedTrials only
PemvidutideIMPACT (2025) · Human randomized trial
MASH resolution without worsening fibrosis occurred in 58% and 52% of the pemvidutide groups versus 20% with placebo. Fibrosis improvement without worsening MASH was 33% and 36% versus 28%; these fibrosis comparisons were not statistically significant.
Limitation: Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial.
Studied: 212 adults with biopsy-confirmed MASH and F2 or F3 fibrosis.
Not approvedTrials only
Peptide YYPYY3-36 with and without GLP-1 (2014) · Human randomized crossover study
Neither individual infusion significantly reduced food intake in this experiment. The combination reduced intake by 30.4%; nausea increased slightly.
Limitation: An acute combined-hormone effect cannot be transferred to PYY alone or interpreted as sustained weight loss.
Studied: 25 overweight healthy men.
Not approvedTrials only
PramlintideAdjunct-to-insulin trial (2006) · Human randomized trial
HbA1c declined by 0.5 percentage points in both groups. Weight changed by −1.3 kg with pramlintide versus +1.2 kg with placebo. Post-meal glucose excursions improved more with pramlintide. Nausea occurred in 63% versus 36%; severe hypoglycemia event rates were 0.57 versus 0.30 per patient-year.
Limitation: The glucose-management protocol included clinician-directed insulin adjustment. A favorable meal-glucose finding should not be described as superior HbA1c reduction or used as a self-treatment protocol.
Studied: 296 people with type 1 diabetes.
WithdrawnFDA label
RetatrutideTriple-receptor obesity trial (2023) · Human phase 2 randomized trial
At 48 weeks, average weight reduction reached 24.2% in the highest studied group versus 2.1% with placebo. Gastrointestinal events and dose-related heart-rate increases were reported.
Limitation: This early efficacy trial does not establish long-term outcomes or verify commercial “R” products. Study doses describe the trial, not instructions for using research chemicals.
Studied: 338 adults with obesity, or overweight with a weight-related condition.
Not approvedTrials only
SurvodutideSYNCHRONIZE-1 (2026) · Human randomized trial
Mean weight changes in the treatment-regimen analysis were −12.2% and −13.0% versus −5.4% with placebo. Gastrointestinal adverse events occurred in 80.9%, 89.7%, and 47.9%, respectively.
Limitation: The analysis included treatment discontinuation and other weight-management interventions. Its percentages should not be mixed with results using different estimands. Boehringer Ingelheim funded the study.
Studied: 725 adults without diabetes who had obesity, or overweight with an associated condition.
Not approvedTrials only
UBT25124-week phase 2 trial in adults with overweight or obesity in China (2026) · Human randomized phase 2 trial
Average weight change at 24 weeks ranged from about -13.6% to -19.7% across UBT251 dose groups, versus -2.0% with placebo; after subtracting the placebo result, the differences were about 11.5 to 17.7 percentage points. Waist size, BMI, blood pressure, blood fats and blood sugar measures also improved. The most frequent side effects were mild to moderate digestive symptoms.
Limitation: One 24-week phase 2 trial of 205 people in China, run and funded by the developer. It is too short to show whether weight loss continues or is maintained, it did not compare UBT251 with approved drugs, and it cannot show effects on heart disease or long-term safety. Phase 3 trials registered in 2026 had not reported results when this page was checked.
Studied: 205 adults aged 18 to 61 with overweight or obesity and without type 2 diabetes, at multiple research centers in China; 59% women.
Not approvedTrials only
Small or uncontrolled human studies (1)Human reports without randomization, such as pilots, case series or open-label studies.
NisotirostideDiscovery-to-clinic phase 1 study (2026) · Human phase 1 study with separate preclinical experiments
Mean weight difference versus placebo was −0.75 kg with nisotirostide alone, which was not statistically significant. Added to dulaglutide, a difference of up to −2.58 kg versus dulaglutide alone was reported (P<0.05). Nausea and vomiting were the most common adverse events, described as dose-dependent and mild to moderate.
Limitation: Small, early, single-administration research cannot establish sustained effectiveness or long-term safety. Follow-up duration, subgroup sizes, confidence intervals, and detailed allocation methods are not supplied in the abstract. A pharmacokinetic rationale for weekly development is not an established treatment schedule.
Studied: 65 participants in the phase 1 study, including healthy participants and participants with type 2 diabetes already receiving dulaglutide.…
Not approvedVery limited
Animal and lab studies only (9)No human study in our sources.
5-Amino-1MQSee the profile for the animal and lab research.Not approvedNone
AdipotideSee the profile for the animal and lab research.Not approvedNone
AOD-9604See the profile for the animal and lab research.Not approvedVery limited
HGH Fragment 176-191See the profile for the animal and lab research.Not approvedNone
MOTS-cSee the profile for the animal and lab research.Not approvedNone
Nesfatin-1See the profile for the animal and lab research.Not approvedNone
Neuropeptide YSee the profile for the animal and lab research.Not approvedVery limited
Orexin-ASee the profile for the animal and lab research.Not approvedVery limited
SLU-PP-332See the profile for the animal and lab research.Not approvedNone

Selected studies, not a systematic review. Approval belongs to a specific product and use. Side-by-side comparisons: Semaglutide vs Tirzepatide · Tirzepatide vs Retatrutide · Sermorelin vs Tesamorelin · MOTS-c vs Elamipretide · Ipamorelin vs MK-677 · AOD-9604 vs HGH Fragment 176-191 · Tesamorelin vs CJC-1295 · Eloralintide vs Cagrilintide (all comparisons).

5-Amino-1MQ

5-Amino-1MQ is a small molecule studied as an inhibitor of nicotinamide N-methyltransferase (NNMT). Its featured evidence concerns cultured adipocytes and obese mice, rather than demonstrated weight loss in people.

Related compounds

Read the studies →

Adipotide

Adipotide is a peptidomimetic designed to target blood vessels in adipose tissue. Its featured study reported weight-related changes in obese monkeys and also identified kidney effects.

Research topics

Read the studies →

AOD-9604

AOD-9604 is a modified fragment of growth hormone investigated for metabolic effects. Animal experiments and the later human obesity program tell different parts of its story.

Research topics

Read the studies →

Cagrilintide

Cagrilintide is an amylin analogue investigated for weight management. Its evidence must be separated from evidence for combinations containing it.

Research topics

Read the studies →

Dulaglutide

Dulaglutide, marketed as Trulicity, is a long-acting GLP-1 receptor agonist used in type 2 diabetes care. Its research includes blood-sugar control and cardiovascular outcomes.

Prescription medicines

Read the studies →

Efpeglenatide

Efpeglenatide is an exendin-based GLP-1 receptor agonist. AMPLITUDE-O examined cardiovascular and kidney outcomes in a high-risk type 2 diabetes population.

Research topics

Read the studies →

Eloralintide

Eloralintide is an experimental weight-loss drug from Eli Lilly that acts on amylin receptors instead of the GLP-1 receptor used by semaglutide and tirzepatide. In a 48-week phase 2 trial, average weight loss ranged from about 9% to 20% across dose groups, versus 0.4% on placebo. It is not approved, and phase 3 trials began in 2025 and 2026.

Investigational

Read the studies →

Exenatide

Exenatide is an incretin medicine used in type 2 diabetes. Short-acting and extended-release products need to be distinguished when reading evidence.

Prescription medicines

Read the studies →

Ghrelin

Ghrelin is a peptide hormone involved in appetite signaling. A small human crossover experiment found higher food intake after an acute infusion.

Research topics

Read the studies →

Glucagon

Glucagon is a hormone medicine used to raise dangerously low blood glucose. It serves a different role from medicines aimed at lowering glucose or weight.

Prescription medicines

Read the studies →

HGH Fragment 176-191

HGH Fragment 176-191 is a label for a growth-hormone C-terminal fragment. The selected primary paper studied the related 177-191 fragment, so it is background evidence rather than confirmation of the exact 176-191 product.

Research topics

Read the studies →

Human insulin

Human insulin replaces or supplements insulin activity in diabetes. Different formulations have different onset and duration, making product identity especially important.

Prescription medicines

Read the studies →

L-Carnosine

L-Carnosine is a dipeptide investigated in metabolic and cellular research. A small oral-supplement pilot examined insulin and glucose-related measures in adults without diabetes.

Research topics

Read the studies →

Liraglutide

Liraglutide is an incretin medicine with distinct diabetes and weight-management product contexts. Its benefits should be tied to the exact indication and population.

Prescription medicines

Read the studies →

Lixisenatide

Lixisenatide is a GLP-1 receptor agonist. ELIXA studied cardiovascular safety in people with type 2 diabetes who had recently experienced an acute coronary event.

Research topics

Read the studies →

Mazdutide

Mazdutide is a weekly injected peptide that activates both GLP-1 and glucagon receptors. Eli Lilly discovered it and Innovent develops it in China, where it was approved in 2025 for weight management and for type 2 diabetes, the first drug of its kind approved anywhere. It is not approved in the US or Europe.

Research topics

Read the studies →

MK-677

MK-677, or ibutamoren, is a small-molecule ghrelin mimetic. A trial in older adults found increased fat-free mass without an improvement in strength or physical function.

Related compounds

Read the studies →

MOTS-c

MOTS-c is a 16-amino-acid peptide studied as a mitochondrial signal. Its metabolic research is frequently discussed alongside exercise and aging.

Research topics

Read the studies →

Nesfatin-1

Nesfatin-1 is a NUCB2-derived peptide investigated in feeding regulation. Its foundational evidence involved central administration and signaling experiments in rats.

Research topics

Read the studies →

Neuropeptide Y

Neuropeptide Y is an endogenous signaling peptide involved in feeding circuitry. The selected mouse study examined NPY-related neurons and feeding behavior rather than a clinical peptide treatment.

Research topics

Read the studies →

Nisotirostide

Nisotirostide is a selective NPY2 receptor agonist investigated as an adjunct to GLP-1 treatment. The selected publication combines laboratory experiments with a small phase 1 human study.

Investigational

Read the studies →

Orexin-A

Orexin-A, also known as hypocretin-1, is a hypothalamic signaling peptide. The foundational paper identified orexin peptides and receptors and studied feeding responses in rats.

Research topics

Read the studies →

Orforglipron

Orforglipron is a once-daily pill that activates the GLP-1 receptor, the same target as semaglutide and tirzepatide. Unlike them it is not a peptide but a small-molecule drug, which is why it works as a tablet without food or water rules. The FDA approved it in April 2026 as Foundayo for weight management in adults with obesity, or overweight with a weight-related condition.

Prescription medicines

Read the studies →

Pemvidutide

Pemvidutide is Altimmune's experimental weekly injected peptide that activates GLP-1 and glucagon receptors in equal measure. It produced weight loss in a phase 2 obesity trial, and in a phase 2b trial in MASH it resolved the disease in about half of people but did not significantly improve liver scarring. It is not approved anywhere.

Research topics

Read the studies →

Peptide YY

Peptide YY is a gut-hormone family involved in feeding regulation. The selected trial studied PYY3-36 alone and with GLP-1; the combined result should not be described as a proven PYY-alone effect.

Research topics

Read the studies →

Pramlintide

Pramlintide is an adjunctive diabetes medicine used with mealtime insulin in selected patients. It does not replace insulin.

Prescription medicines

Read the studies →

Retatrutide

Retatrutide is a triple-receptor agonist investigated for obesity and related metabolic conditions. Its trial identity differs from unverified coded seller listings.

Investigational

Read the studies →

Semaglutide

Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.

Prescription medicines

Read the studies →

Setmelanotide

Setmelanotide is a melanocortin-4 receptor agonist studied in rare genetic forms of obesity. The featured trials enrolled people with POMC or LEPR deficiency, rather than general-population obesity.

Prescription medicines

Read the studies →

SLU-PP-332

SLU-PP-332 is a lab-made small molecule, not a peptide, that switches on the estrogen-related receptors involved in how muscle burns fuel. It is called an "exercise mimetic" because in mice it triggered some of the same metabolic changes as aerobic exercise. All published evidence comes from animal and cell studies.

Related compounds

Read the studies →

Survodutide

Survodutide is a dual GLP-1 and glucagon receptor agonist. A 2026 phase 3 publication reports weight outcomes in adults with obesity or overweight without diabetes.

Research topics

Read the studies →

Tesamorelin

Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.

Prescription medicines

Read the studies →

Tirzepatide

Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.

Prescription medicines

Read the studies →

UBT251

UBT251 is an experimental weight-loss and diabetes drug that acts on three hormone receptors at once, GLP-1, GIP and glucagon, the same combination targeted by Eli Lilly's retatrutide. It was developed by The United Laboratories in China and licensed to Novo Nordisk in 2025. In a 24-week phase 2 trial in China, average weight loss ranged from about 14% to 20% across dose groups, versus 2.0% with placebo. It is not approved anywhere.

Investigational

Read the studies →

See something wrong on this page? Report a mistake · Corrections

FREE PEPSRADAR ACCOUNT

We check sellers’ lab reports with the testing labs themselves.

So far 89 of the 105 lab reports we looked up matched the testing lab’s own record, and 12 did not.

A free account shows which sellers, report by report, plus daily prices, deals, Ask PepsRadar and alerts. If you want it, the PepsRadar Weekly brings new research and FDA news once a week. No dosing advice.

Create a free accountWhat members get →